Zydus Lifesciences Launches ANVIMO, a Breakthrough for Transplant Patients

Zydus Lifesciences Limited, a leading lifesciences company, has launched ANVIMO, a breakthrough medication for transplant patients in India. This new drug, available in dosages of 240 mg and 480 mg, has been developed to prevent Cytomegalovirus (CMV) infection in haematopoietic stem cell transplant and kidney transplant patients. By providing an affordable and accessible treatment option, Zydus Lifesciences is committed to improving the survival rates and quality of life for transplant patients. The company's mission is to deliver world-class healthcare solutions and unlock new possibilities in lifesciences.

Zydus Lifesciences Ltd is a pharmaceutical company that develops, manufactures, and markets a wide range of generic and branded formulations, over-the-counter products, and active pharmaceutical ingredients (APIs).

Top Pharmaceuticals Stocks

Stock Name	MCap(Cr)	P/E Ratio	3Y Stock Ret.
Stock Name	MCap(Cr)	P/E Ratio	3Y Stock Ret.
Sun Pharmaceutical Industries Ltd NSE: SUNPHARMA	3,82,274	32.42	24.74%
Divi'S Laboratories Ltd NSE: DIVISLAB	1,45,483	70.38	9.62%
Cipla Ltd NSE: CIPLA	1,13,671	22.82	15.1%
Torrent Pharmaceuticals Ltd NSE: TORNTPHARM	99,772	53.58	28.6%
Mankind Pharma Ltd NSE: MANKIND	94,505	48.87	-